Schering-Plough PEG-Intron
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Peginterferon alfa-2b is approved Aug. 7 for combination use with Schering's Rebetol (ribavirin) capsules for treatment of chronic hepatitis C in patients with compensated liver disease who have not been previously treated with interferon alfa and are at least 18 years old. PEG-Intron was initially approved as monotherapy for hepatitis C Jan. 19. Rebetol received approval July 25 as a separately marketed product for use in combination with Schering's Intron A (interferon alfa-2b, recombinant); previously, the agent was only available as part of a package with Intron
You may also be interested in...
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.